Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.415 USD | -2.15% | -9.29% | -70.57% |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 4.825 | 3.104 | 2.905 | - | - |
Enterprise Value (EV) 1 | 4.825 | 3.104 | 2.905 | 2.905 | 2.905 |
P/E ratio | -0.24 x | -0.22 x | -0.1 x | -0.13 x | -0.17 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 0.53 x | 0.54 x | 0.53 x | 0.26 x |
EV / Revenue | - | 0.53 x | 0.54 x | 0.53 x | 0.26 x |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | -1,489,958 x | - | - | - |
FCF Yield | - | -0% | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 2,071 | 2,201 | 7,000 | - | - |
Reference price 2 | 2.330 | 1.410 | 0.4150 | 0.4150 | 0.4150 |
Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 5.822 | 5.409 | 5.475 | 11.03 |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -13.62 | -14.75 | -14.99 | -11.34 |
Operating Margin | - | -233.88% | -272.64% | -273.84% | -102.84% |
Earnings before Tax (EBT) 1 | - | -8.163 | -13.44 | -15.6 | -11.95 |
Net income 1 | -20.04 | -13.81 | -19.3 | -15.6 | -11.95 |
Net margin | - | -237.26% | -356.91% | -285.02% | -108.39% |
EPS 2 | -9.680 | -6.350 | -4.050 | -3.260 | -2.490 |
Free Cash Flow | - | -2.083 | - | - | - |
FCF margin | - | -35.77% | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|
Net sales 1 | -0.3642 | 1.389 | 1.397 | 1.34 | 1.283 |
EBITDA | - | - | - | - | - |
EBIT 1 | -5.039 | -3.928 | -3.518 | -3.606 | -3.695 |
Operating Margin | 1,383.29% | -282.85% | -251.83% | -269.1% | -288% |
Earnings before Tax (EBT) 1 | 0.3182 | -2.163 | -3.671 | -3.759 | -3.848 |
Net income 1 | -4.994 | -8.027 | -3.671 | -3.759 | -3.848 |
Net margin | 1,370.99% | -577.97% | -262.78% | -280.52% | -299.92% |
EPS 2 | -2.170 | -1.690 | -0.7700 | -0.7900 | -0.8100 |
Dividend per Share | - | - | - | - | - |
Announcement Date | 4/1/24 | 5/15/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | -2.08 | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.57% | 2.91M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- PTPI Stock
- Financials Petros Pharmaceuticals, Inc.